Quantcast

Latest CRLX101 Stories

2014-05-05 20:23:52

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/renal_cell_carcinoma_global_clinical_trials_review.htmlRenal Cell Carcinoma Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Renal Cell Carcinoma...

2014-05-05 08:29:46

SAN DIEGO, May 5, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin(®) (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. The open-label study is expected to enroll up to 64...

2014-03-18 08:33:40

CAMBRIDGE, Mass., March 18, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2 trial designed to (1) identify the recommended Phase 2 dose of CRLX101 in combination with Xeloda(®) (capecitabine) and radiation (chemoradiotherapy) and (2) detect signals, if any, of increased efficacy over standard neoadjuvant chemoradiotherapy for rectal cancer. The trial is...

2014-02-11 08:33:10

CAMBRIDGE, Mass., Feb. 11, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in an open label single-arm Phase 2 clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in patients with relapsed ovarian cancer. The Phase 2 combination therapy trial of this investigational treatment is being conducted at Massachusetts General Hospital (MGH) and...

2014-01-13 08:29:57

CAMBRIDGE, Mass., Jan. 13, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved its primary efficacy endpoint in an ongoing single-arm Phase 2 monotherapy clinical trial in relapsed ovarian cancer. The ongoing open label Phase 2 monotherapy trial is being conducted at Massachusetts General Hospital and the affiliated Harvard teaching hospitals under the direction of principal investigator,...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.